These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The inferiority of noninferiority trials. Udayasiri DK; Skandarajah A; Hayes IP ANZ J Surg; 2020 Mar; 90(3):203-205. PubMed ID: 32147920 [No Abstract] [Full Text] [Related]
8. Assessing noninferiority: Evaluating efficacy of a new treatment without complete data. Gao P; Odem-Davis K Pharm Stat; 2019 Oct; 18(5):546-554. PubMed ID: 30977258 [TBL] [Abstract][Full Text] [Related]
9. Noninferiority Clinical Trials: The Good, the Bad, and the Ugly. Lesaffre E Semin Liver Dis; 2018 May; 38(2):97-102. PubMed ID: 29871016 [TBL] [Abstract][Full Text] [Related]
10. Potential of Control Conditions for Nonspecific Treatment Effects in Noninferiority Trials. Budde H; Amatriain-Fernández S; Trautmann S JAMA Psychiatry; 2023 May; 80(5):522-523. PubMed ID: 36920358 [No Abstract] [Full Text] [Related]
11. Potential of Control Conditions for Nonspecific Treatment-Effects in Noninferiority Trials-Reply. Hoge EA; Bui E; Simon NM JAMA Psychiatry; 2023 May; 80(5):523. PubMed ID: 36920354 [No Abstract] [Full Text] [Related]
12. Noninferiority Clinical Trials: Overview for the Clinical Cardiologist. Murphy SA; Bellavia A Circulation; 2024 Sep; 150(11):823-825. PubMed ID: 39250539 [No Abstract] [Full Text] [Related]
13. Reduced-Frequency Endocrine Therapy and Challenges of Noninferiority Study Designs. Fabian CJ; Mudaranthakam DP JAMA Oncol; 2023 May; 9(5):672-674. PubMed ID: 36951870 [No Abstract] [Full Text] [Related]
14. The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology. Jatoi I; Gail MH JAMA Oncol; 2020 Mar; 6(3):420-424. PubMed ID: 31830235 [TBL] [Abstract][Full Text] [Related]
15. Users' guide to the surgical literature: how to assess a noninferiority trial. Thoma A; Farrokhyar F; Waltho D; Braga LH; Sprague S; Goldsmith CH Can J Surg; 2017 Dec; 60(6):426-432. PubMed ID: 29173262 [TBL] [Abstract][Full Text] [Related]
16. Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. Althunian TA; de Boer A; Groenwold RHH; Klungel OH J Clin Epidemiol; 2018 Dec; 104():15-23. PubMed ID: 30009941 [TBL] [Abstract][Full Text] [Related]
17. Some issues for the evaluation of noninferiority trials. Xie X; Wang M; Ng V; Sikich N J Comp Eff Res; 2018 Sep; 7(9):835-843. PubMed ID: 30192159 [TBL] [Abstract][Full Text] [Related]
18. Noninferiority studies with multiple reference treatments. Li-Ching H; Miin-Jye W; Hung CS; Shing KK Stat Methods Med Res; 2017 Jun; 26(3):1295-1307. PubMed ID: 25792542 [TBL] [Abstract][Full Text] [Related]